Revolution Medicines stole the day's biggest headline. An experimental pill showed meaningful results against pancreatic cancer — one of the deadliest tumour types. The AP story ranks as the highest-impact news of the morning. Options traders had already been positioning ahead of the catalyst. Short interest in RVMD sits at elevated levels, making this a high-stakes moment for bears.
A packed calendar kicks off today. Ulta Beauty reports Monday after the bell. Dollar General and Macy's follow Tuesday. Medtronic prints Wednesday — and analysts are already cutting targets into the number. Thursday brings Ciena and . The consumer and defence-adjacent names dominate the slate.
OKLO is the week's most contested setup. Short interest jumped 21% in seven days to 23.5% of free float. Borrow availability is just 9.8% of SI. Squeeze risk is real with earnings due June 3. Meanwhile, Rubrik is seeing the opposite — options bulls have taken full control ahead of its own June 3 print. SAIC call buying hit a year-low put/call ratio, signalling strong bullish conviction from options traders.
European stocks slid broadly, but the defence sector rallied after Ukraine ratified a $105 billion EU loan deal. Separately, Dulux maker AkzoNobel surged after rejecting a $14.5 billion takeover bid. Oil stayed below $100 despite Chevron's CEO warning of a summer supply squeeze linked to the Strait of Hormuz blockade.
Three of the week's biggest insider filings stand out. Twilio saw a $184 million board-level sale. The Walton family offloaded over $250 million in Walmart stock. Ralph Lauren filed a $100 million sale in RL. Analysts, however, remained bullish — lifting targets sharply on Dell and F5 on AI infrastructure tailwinds.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
